ResMed is leveraging the popularity of Ozempic-style weight loss drugs to enhance screenings for sleep apnea, reporting ...

We came across a bullish thesis on ResMed Inc. on Best Anchor Stocks’s Substack. In this article, we will summarize the bulls ...

ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business ...

Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and ...

Resmed shares are down a bit today, even though second-quarter results came in ahead of the consensus forecast.

Resmed has beaten expectations with $2 billion in second-quarter revenue and says weight loss drugs are actually boosting ...

Q2 FY2026 earnings call recap: 11% revenue growth, margin expansion, AI innovation, and updated 62–63% guidance—read key takeaways now.

SAN DIEGO – Resmed reported revenue increased 11% to $1.4 billion for its second quarter of fiscal year 2026. Other financial results: Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 ...

Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps ...

Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep apnea.

(RMD) on Thursday reported fiscal second-quarter net income of $392.6 million. On a per-share basis, the San Diego-based company said it had net income ...

Sleep apnea is a serious condition, causing breathing to stop and start several times during sleep. The most common form of the condition is obstructive sleep apnea, where the throat narrows, blocking ...